DDInter1400 DDInter1435
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Pazopanib {u} (Compound) treats {v} (Disease) kidney cancer
Pazopanib {u} (Compound) binds {v} (Gene) PIP4K2C
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
Pazopanib {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C8 Inhibitors
Pazopanib {u} (Compound) downregulates {v} (Gene) MEST
Pazopanib {u} (Compound) causes {v} (Side Effect) Rhinorrhoea
Pazopanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Pazopanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perphenazine
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Pazopanib (Compound) treats kidney cancer (Disease)
Pazopanib (Compound) binds PIP4K2C (Gene)
Pazopanib (Compound) upregulates SRC (Gene)
Pazopanib (Compound) is included by Cytochrome P450 2C8 Inhibitors (Pharmacologic Class)
Pazopanib (Compound) downregulates MEST (Gene)
Pazopanib (Compound) causes Rhinorrhoea (Side Effect)
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab